MedTrace Logo

A Trial of the Safety and Efficacy of K-604 for the Treatment of Atherosclerosis

NCT00851500 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 210

Last updated 2011-08-17

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of K-604 for the treatment of atherosclerosis.

Conditions

Interventions

DRUG

K-604

K-604 is given for 26 weeks

OTHER

Placebo

placebo tablets are given for 26 weeks

Sponsors & Collaborators

  • Kowa Research Institute, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2011-06-30
Completion
2011-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00851500 on ClinicalTrials.gov